Twenty-year time trends in use of evidence-based heart failure drug therapy in Denmark

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Standard

Twenty-year time trends in use of evidence-based heart failure drug therapy in Denmark. / Vinter, Nicklas; Jensen, Martin; Skjøth, Flemming; Larsen, Torben Bjerregaard; Frost, Lars; Johnsen, Søren Paaske.

I: Basic & Clinical Pharmacology & Toxicology, Bind 127, Nr. 1, 07.2020, s. 30-38.

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Harvard

Vinter, N, Jensen, M, Skjøth, F, Larsen, TB, Frost, L & Johnsen, SP 2020, 'Twenty-year time trends in use of evidence-based heart failure drug therapy in Denmark', Basic & Clinical Pharmacology & Toxicology, bind 127, nr. 1, s. 30-38. https://doi.org/10.1111/bcpt.13392

APA

Vinter, N., Jensen, M., Skjøth, F., Larsen, T. B., Frost, L., & Johnsen, S. P. (2020). Twenty-year time trends in use of evidence-based heart failure drug therapy in Denmark. Basic & Clinical Pharmacology & Toxicology, 127(1), 30-38. https://doi.org/10.1111/bcpt.13392

CBE

Vinter N, Jensen M, Skjøth F, Larsen TB, Frost L, Johnsen SP. 2020. Twenty-year time trends in use of evidence-based heart failure drug therapy in Denmark. Basic & Clinical Pharmacology & Toxicology. 127(1):30-38. https://doi.org/10.1111/bcpt.13392

MLA

Vancouver

Vinter N, Jensen M, Skjøth F, Larsen TB, Frost L, Johnsen SP. Twenty-year time trends in use of evidence-based heart failure drug therapy in Denmark. Basic & Clinical Pharmacology & Toxicology. 2020 jul;127(1):30-38. https://doi.org/10.1111/bcpt.13392

Author

Vinter, Nicklas ; Jensen, Martin ; Skjøth, Flemming ; Larsen, Torben Bjerregaard ; Frost, Lars ; Johnsen, Søren Paaske. / Twenty-year time trends in use of evidence-based heart failure drug therapy in Denmark. I: Basic & Clinical Pharmacology & Toxicology. 2020 ; Bind 127, Nr. 1. s. 30-38.

Bibtex

@article{95f387464223471a8f2c4b62d1d4d563,
title = "Twenty-year time trends in use of evidence-based heart failure drug therapy in Denmark",
abstract = "European guidelines for heart failure (HF) have continuously incorporated new evidence since the first publication in 1995. We aimed to explore time trends in utilisation of pharmacological treatment for HF and dispensing of recommended dosages among patients with a first-time diagnosis of HF. We performed a historical cohort study of patients with a first-time HF diagnosis from 1997 to 2015, identified in the Danish National Patient Registry. Dispensed pharmacological treatment included angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), beta-blockers, mineralocorticoid receptor blockers (MRAs), digoxin and diuretics. Furthermore, we estimated the proportion of patients receiving the recommended target dosages 1 year after the diagnosis. The utilisation increased and correlated with publication of landmark studies, and among patients diagnosed in 2015, approximately two of three received ACEI/ARB and beta-blocker, respectively. Less than half of the patients redeeming prescriptions for ACEIs, ARBs, beta-blockers or MRAs received the recommended target dosages. The utilisation of pharmacological therapy for HF appears to be correlated with the publications of landmark Phase III clinical trials. However, a high proportion of patients do not receive the recommended target dosages. Despite improvements over time, a substantial gap appears to remain between guideline recommendations and pharmacological therapy in routine care.",
keywords = "DIAGNOSIS, ESC GUIDELINES, EUROPEAN-SOCIETY, OUTCOMES, QUALITY, REGISTRY, dosage, drug utilisation, guidelines, heart failure, trends",
author = "Nicklas Vinter and Martin Jensen and Flemming Skj{\o}th and Larsen, {Torben Bjerregaard} and Lars Frost and Johnsen, {S{\o}ren Paaske}",
note = "{\textcopyright} 2020 Nordic Association for the Publication of BCPT (former Nordic Pharmacological Society).",
year = "2020",
month = jul,
doi = "10.1111/bcpt.13392",
language = "English",
volume = "127",
pages = "30--38",
journal = "Basic & Clinical Pharmacology & Toxicology",
issn = "1742-7835",
publisher = "Wiley-Blackwell Publishing Ltd.",
number = "1",

}

RIS

TY - JOUR

T1 - Twenty-year time trends in use of evidence-based heart failure drug therapy in Denmark

AU - Vinter, Nicklas

AU - Jensen, Martin

AU - Skjøth, Flemming

AU - Larsen, Torben Bjerregaard

AU - Frost, Lars

AU - Johnsen, Søren Paaske

N1 - © 2020 Nordic Association for the Publication of BCPT (former Nordic Pharmacological Society).

PY - 2020/7

Y1 - 2020/7

N2 - European guidelines for heart failure (HF) have continuously incorporated new evidence since the first publication in 1995. We aimed to explore time trends in utilisation of pharmacological treatment for HF and dispensing of recommended dosages among patients with a first-time diagnosis of HF. We performed a historical cohort study of patients with a first-time HF diagnosis from 1997 to 2015, identified in the Danish National Patient Registry. Dispensed pharmacological treatment included angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), beta-blockers, mineralocorticoid receptor blockers (MRAs), digoxin and diuretics. Furthermore, we estimated the proportion of patients receiving the recommended target dosages 1 year after the diagnosis. The utilisation increased and correlated with publication of landmark studies, and among patients diagnosed in 2015, approximately two of three received ACEI/ARB and beta-blocker, respectively. Less than half of the patients redeeming prescriptions for ACEIs, ARBs, beta-blockers or MRAs received the recommended target dosages. The utilisation of pharmacological therapy for HF appears to be correlated with the publications of landmark Phase III clinical trials. However, a high proportion of patients do not receive the recommended target dosages. Despite improvements over time, a substantial gap appears to remain between guideline recommendations and pharmacological therapy in routine care.

AB - European guidelines for heart failure (HF) have continuously incorporated new evidence since the first publication in 1995. We aimed to explore time trends in utilisation of pharmacological treatment for HF and dispensing of recommended dosages among patients with a first-time diagnosis of HF. We performed a historical cohort study of patients with a first-time HF diagnosis from 1997 to 2015, identified in the Danish National Patient Registry. Dispensed pharmacological treatment included angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), beta-blockers, mineralocorticoid receptor blockers (MRAs), digoxin and diuretics. Furthermore, we estimated the proportion of patients receiving the recommended target dosages 1 year after the diagnosis. The utilisation increased and correlated with publication of landmark studies, and among patients diagnosed in 2015, approximately two of three received ACEI/ARB and beta-blocker, respectively. Less than half of the patients redeeming prescriptions for ACEIs, ARBs, beta-blockers or MRAs received the recommended target dosages. The utilisation of pharmacological therapy for HF appears to be correlated with the publications of landmark Phase III clinical trials. However, a high proportion of patients do not receive the recommended target dosages. Despite improvements over time, a substantial gap appears to remain between guideline recommendations and pharmacological therapy in routine care.

KW - DIAGNOSIS

KW - ESC GUIDELINES

KW - EUROPEAN-SOCIETY

KW - OUTCOMES

KW - QUALITY

KW - REGISTRY

KW - dosage

KW - drug utilisation

KW - guidelines

KW - heart failure

KW - trends

U2 - 10.1111/bcpt.13392

DO - 10.1111/bcpt.13392

M3 - Journal article

C2 - 32003944

VL - 127

SP - 30

EP - 38

JO - Basic & Clinical Pharmacology & Toxicology

JF - Basic & Clinical Pharmacology & Toxicology

SN - 1742-7835

IS - 1

ER -